Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  immunomodulation therapy, immunotherapy
Results 1-25 of 1834 for your search:
Start Over
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Status: Active
Phase: Phase IV
Type: Treatment
Age: Any age
Trial IDs: CRAD001C2X01B, NCI-2013-01151, NCT01789281
Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer and Hepatitis C Infection
Status: Active
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-213, NCI-2013-01103, NCT01849588
Expanded Access Protocol of Blinatumomab in Pediatric and Adolescent Subjects With Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Status: Active
Phase: Phase IV
Type: Treatment
Age: 28 days to 17 years
Trial IDs: 20130320, NCI-2015-00115, NCT02187354
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CA209-920, NCI-2017-00140, NCT02982954
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Clofarabine and Cytarabine or Standard Induction Therapy and Chemotherapy with or without Natural Killer Cell Transplant in Treating Younger Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: AML08, NCI-2011-03659, NCT00703820
Radiation Therapy with Cisplatin, Docetaxel, or Cetuximab and Docetaxel after Surgery in Treating Patients with High-Risk Stage III-IV Squamous Cell Head and Neck Cancer
Status: Temporarily closed
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG-1216, NCI-2013-00500, NCT01810913
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, S1400I, NCT02154490
Radiation Therapy with or without Combination Chemotherapy or Pazopanib Hydrochloride before Surgery in Treating Patients with Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 and over
Trial IDs: ARST1321, NCI-2014-01340, NCT02180867
Nivolumab and Ipilimumab with or without Sargramostim in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6141, NCI-2014-02674, NCT02339571
Afatinib Dimaleate with or without Cetuximab in Treating Patients with Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1403, NCI-2014-02405, BI 1200.124, NCT02438722
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY005, NCI-2015-00651, NCT02502266
A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and under
Trial IDs: NI-0501-04, NCI-2016-00657, 2012-003632-23, NCT01818492
Pegylated Liposomal Doxorubicin Hydrochloride with Atezolizumab and/or Bevacizumab in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Not yet active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY009, NCI-2016-01081, NCT02839707
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UTX-TGR-205, NCI-2016-01433, NCT02793583
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
Status: Active
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 471501, NCI-2016-01887, NCT02956122
Sorafenib Long Term Extension Program (STEP)
Status: Active
Phase: Phase III
Type: Treatment
Age: 16 and over
Trial IDs: 12311, NCI-2012-01207, 2007-002604-17, NCT00625378
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: LF-0208, NCI-2009-01425, NCT00706862
TK008: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TK008, NCI-2011-03649, 2009-012973-37, NCT00914628
Radiation Therapy with or without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG-0920, NCI-2011-00878, CDR0000651536, NCT01311063, NCT00956007
Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 0 to 21
Trial IDs: SJBC3, NCI-2011-01251, NCI-2010-00129, NCT01046825
Start Over